Par Pharmaceutical Companies, Inc. announced that it acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon. Under terms of the agreement, Par will own the ANDAs of fentanyl citrate lozenges, a generic version of Actiq, and cyclobenzaprine ER capsules, the generic version of Amrix, as well as the US rights to market modafinil tablets, the generic version of Provigil.
According to IMS Health data, annual sales in the US for Actiq and the equivalent generic products are $173 million. Annual sales in the US for Provigil and Amrix are approximately $1.1 billion and $125 million, respectively.
Par is currently shipping to the trade all strengths of fentanyl citrate lozenges that were previously available from Teva. Cyclobenzaprine ER capsules and modafinil tablets were not previously marketed by Teva and are not yet available.
Par Pharmaceutical Companies, Inc. is a US-based specialty pharmaceutical company, it develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.